Skip to main content

Thomas Lodise, PhD, PharmD

Authored Items
Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models
Thomas Lodise, PhD, PharmD, Kenneth LaPensee, PhD, MPH
June/July 2019 Vol 12, No 4 in Business, Original Research
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
Kenneth LaPensee, PhD, MPH, Rohit Mistry, MPharm, MBA, MSc, Thomas Lodise, PhD, PharmD
February 2019, Vol 12, No 1, Supplement 1: Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
Kenneth LaPensee, PhD, MPH, Rohit Mistry, MPharm, MBA, MSc, Thomas Lodise, PhD, PharmD
February 2019, Vol 12, No 1, Supplement 2: Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Kenneth LaPensee, PhD, MPH, Michael F. Murphy, MD, PhD, Thomas Lodise, PhD, PharmD
December 2018 Vol 11, No 9 in Business, Original Research
Last modified: September 10, 2019